Radiation
Stereotactic Ablative Body Radiation (SABR)
Stereotactic Ablative Body Radiation (SABR) is a radiation therapy with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
RADIATION
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph not_applicable
1
25%
Ph phase_1
1
25%
Ph phase_2
2
50%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Terminated(1)
Detailed Status
Terminated1
Active, not recruiting1
Recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (25.0%)
Phase 22 (50.0%)
N/A1 (25.0%)
Trials by Status
terminated125%
active_not_recruiting125%
recruiting125%
completed125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingnot_applicable
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT05679674
active_not_recruitingphase_2
SAbR For Oligometastatic Renal Cell Carcinoma
NCT02956798
completedphase_2
SAbR For Oligo-Progressive Renal Cell Cancer.
NCT03696277
terminatedphase_1
Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
NCT03321747
Clinical Trials (4)
Showing 4 of 4 trials
NCT05679674Not Applicable
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT02956798Phase 2
SAbR For Oligometastatic Renal Cell Carcinoma
NCT03696277Phase 2
SAbR For Oligo-Progressive Renal Cell Cancer.
NCT03321747Phase 1
Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung
All 4 trials loaded
Drug Details
- Intervention Type
- RADIATION
- Total Trials
- 4